Prognostic significance of HIF-2α/EPAS1 expression in hepatocellular carcinoma

Figure 1 Representative examples of immunohistochemical staining for HIF-2α/EPASE1, VEGF, and CD31 in HCC. A: Strong cytoplasmic immunore-activity of HIF-2α/EPASE1 is observed in cancers cells (× 400). B: Strong staining in the cytoplasm of noncancerous cirrhotic tissue (× 400). C: HIF-2α/EPAS1-positive staining in perinecrotic area (N) and D: In the cytoplasm of macrophages (× 400). E: Parallel studies of VEGF protein (cytoplasmic staining) and F: CD31 (for microvessels) immunohistochemistry performed on HCC (× 200).

Figure 2 The overall 7-year survival curves of patients with positive HIF-2α/EPAS1 and negative HIF-2α/EPAS1 are shown for the entire cohort, P = 0. 003 (A), as well as patients with venous invasion and without venous invasion, P = 0.014 (B).